SecSonar.com

Tekla Life Sciences Investors (HQL)

Tekla Life Sciences Investors at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Tekla Life Sciences Investors (HQL) is a Asset Management company based in US with a market capitalization of $543.1M. Revenue declined 0.3% year-over-year and free cash flow was negative at -$2.3M. This page tracks HQL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · IPO May 1, 1992

Valuation

Valuation & price

$17.78 · as of May 17, 2026 · -11.6% vs 52w high

6.0

P/E ratio

Latest-FY diluted EPS

1.06

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$20.12$16.52$12.93Jul 25Dec 25Jul 26Jul 7, 25$12.93Jul 9, 25$13.25Jul 11, 25$13.08Jul 15, 25$12.96Jul 17, 25$13.16Jul 21, 25$13.01Jul 23, 25$13.40Jul 25, 25$13.38Jul 29, 25$13.27Jul 31, 25$13.13Aug 4, 25$13.33Aug 6, 25$13.20Aug 11, 25$13.20Aug 13, 25$13.67Aug 15, 25$13.86Aug 19, 25$13.99Aug 21, 25$14.05Aug 25, 25$13.63Aug 27, 25$13.86Aug 29, 25$13.95Sep 3, 25$14.16Sep 5, 25$14.32Sep 9, 25$14.25Sep 11, 25$14.27Sep 16, 25$13.94Sep 18, 25$14.15Sep 22, 25$14.12Sep 24, 25$14.38Sep 26, 25$14.89Sep 30, 25$15.51Oct 2, 25$15.57Oct 6, 25$15.66Oct 8, 25$15.98Oct 10, 25$16.00Oct 14, 25$16.21Oct 16, 25$16.58Oct 21, 25$16.82Oct 23, 25$16.39Oct 27, 25$17.35Oct 29, 25$17.49Oct 31, 25$17.75Nov 4, 25$16.63Nov 6, 25$16.06Nov 10, 25$16.08Nov 12, 25$16.98Nov 14, 25$16.97Nov 18, 25$17.25Nov 20, 25$16.84Nov 25, 25$17.35Nov 28, 25$17.67Dec 2, 25$16.91Dec 4, 25$17.19Dec 8, 25$17.21Dec 10, 25$17.26Dec 12, 25$17.14Dec 16, 25$16.81Dec 18, 25$16.67Dec 22, 25$17.10Dec 24, 25$17.29Dec 29, 25$17.01Jan 2, 26$16.77Jan 6, 26$16.65Jan 8, 26$16.77Jan 12, 26$16.75Jan 14, 26$16.86Jan 16, 26$16.61Jan 21, 26$17.00Jan 23, 26$17.26Jan 27, 26$17.29Jan 29, 26$17.06Feb 2, 26$17.16Feb 4, 26$17.07Feb 9, 26$16.93Feb 11, 26$16.95Feb 13, 26$16.98Feb 18, 26$17.50Feb 20, 26$16.78Feb 24, 26$16.82Feb 26, 26$16.64Mar 2, 26$16.39Mar 4, 26$16.34Mar 6, 26$15.87Mar 10, 26$16.75Mar 12, 26$16.62Mar 17, 26$16.62Mar 19, 26$16.28Mar 23, 26$16.18Mar 25, 26$16.68Mar 27, 26$16.05Mar 31, 26$16.27Apr 2, 26$16.84Apr 7, 26$16.95Apr 9, 26$17.22Apr 13, 26$17.49Apr 15, 26$17.81Apr 17, 26$18.01Apr 22, 26$17.68Apr 24, 26$17.27Apr 28, 26$17.53Apr 30, 26$17.50May 4, 26$17.72May 6, 26$18.22May 8, 26$18.19May 12, 26$18.09May 14, 26$18.20May 18, 26$17.67May 20, 26$17.66May 22, 26$17.19May 28, 26$17.67Jun 1, 26$17.60Jun 3, 26$16.93Jun 5, 26$16.92Jun 9, 26$16.78Jun 11, 26$16.86Jun 15, 26$17.16Jun 17, 26$17.86Jun 22, 26$18.34Jun 24, 26$18.89Jun 26, 26$19.25Jul 2, 26$20.12
$12.9352-week range$20.12
Loading valuation history…

Fundamentals

Key fundamentals

$543.1M

Market cap

-0.3%

Revenue growth (YoY)

100.0%

Gross margin

-$2.3M

Free cash flow (USD)

-$75.5K

Net debt

Net cash position

2.9%

Share dilution

2/4

Graham criteria passed

Defensive-investor screen

Financial Services

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$6.3MFY 2017$69.8MFY 2018$2.0MFY 2019$2.4MFY 2020$39.1MFY 2021$45.0MFY 2022$31.9MFY 2023$39.4MFY 2024$86.7MFY 2025$86.4M
$6.3M$86.4M

Free cash flow by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2025$-2.3M
$0-$2.3M

Gross margin by year

2021 → 2025

FY 202186.5%FY 202282.6%FY 202346.4%FY 2024100.0%FY 2025100.0%
86.5%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: —

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

No tracked SEC signals for HQL yet — activity appears here as filings land on EDGAR.

Questions

Frequently asked questions

What is Tekla Life Sciences Investors's market cap?

Tekla Life Sciences Investors (HQL) has a market capitalization of $543.1M.

What is HQL's P/E ratio?

HQL trades at a price-to-earnings ratio of 6.0, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is HQL's price-to-book (P/B) ratio?

HQL trades at 1.06 times book value per share.

Are insiders buying HQL stock?

SEC Form 4 filings show no open-market insider buys at Tekla Life Sciences Investors in the last 90 days (0 sells).

Same arena

Related companies in Asset Management

ECC

Eagle Point Credit Company Inc.

$548.7M

MSIF

MSC Income Fund, Inc.

$557.7M

DXYZ

Destiny Tech100 Inc.

$565.2M

IFN

Aberdeen India Fund, Inc.

$480.7M

GAIN

Gladstone Investment Corporation

$636.4M

MGRB

Affiliated Managers Group, Inc.

$448.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.